Form 4: IOVANCE Interim CEO's RSU Vesting & Tax Withholding

IOVANCE BIOTHERAPEUTICS' Interim CEO, Frederick G. Vogt, reported the vesting of restricted stock units and subsequent share withholding for tax obligations on December 1 and 2, 2025.

Summary

• Frederick G. Vogt, Interim CEO & General Counsel of IOVANCE BIOTHERAPEUTICS, INC. (IOVA), reported transactions related to his beneficial ownership of common stock.
• On December 1, 2025, 41,669 Restricted Stock Units (RSUs) vested, converting into common stock.
• Concurrently, 17,701 shares were disposed of at a price of $2.23 per share to satisfy mandatory tax withholding requirements upon RSU vesting. This was not an open market sale.
• Following these transactions, Vogt beneficially owned 458,531 shares of common stock.
• On December 2, 2025, an additional 10,417 RSUs vested, converting into common stock.
• 4,426 shares were disposed of at a price of $2.14 per share to satisfy mandatory tax withholding requirements for this vesting event. This was also not an open market sale.
• After these transactions, Vogt beneficially owned 464,522 shares of common stock.
• The remaining RSUs from a March 1, 2024 grant total 208,344, and from a March 2, 2023 grant total 10,418, which will vest in equal quarterly installments.

Sentiment

Score: 5

Explanation: The filing is a routine Form 4 detailing scheduled RSU vesting and tax withholding for an executive. It provides no new information that would significantly alter the company's sentiment, being a standard compliance disclosure.

Positives

• Vesting of Restricted Stock Units (RSUs) indicates the executive is receiving compensation as per their employment agreement, aligning their interests with shareholders.
• The executive continues to hold a significant number of shares (464,522 common stock and 218,762 remaining RSUs), demonstrating continued stake in the company's performance.

Negatives

• Shares were withheld by the Issuer to satisfy mandatory tax withholding requirements, which is a standard practice and not an open market sale by the executive. This reduces the executive's direct shareholding slightly but is not a negative signal.

Future Outlook

This filing is a routine report of insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This Form 4 filing details routine executive compensation events (RSU vesting and tax withholding) and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, pre-scheduled compensation events. The executive's continued ownership aligns interests.

Next Steps

• Remaining Restricted Stock Units (RSUs) from the March 1, 2024, and March 2, 2023, grants will continue to vest in equal quarterly installments.

Key Dates

Keywords

IOVANCE BIOTHERAPEUTICS, IOVA, Frederick G. Vogt, Form 4, SEC filing, insider transaction, restricted stock units, RSU vesting, tax withholding, beneficial ownership, executive compensation